Generic Name: meropenem
Applies to meropenem: intravenous powder for solution
In addition to its needed effects, some unwanted effects may be caused by meropenem (the active ingredient contained in Merrem). In the event that any of these side effects do occur, they may require medical attention.

If any of the following side effects occur while taking meropenem, check with your doctor or nurse immediately:
Some of the side effects that can occur with meropenem may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:


Applies to meropenem: intravenous powder for injection, intravenous solution
In clinical trials (n=2904), this drug was discontinued in 1.2% of patients due to side effects; 5 deaths were possibly drug-related.  In a review of 4872 patients, diarrhea, rash, nausea/vomiting, injection site inflammation, thrombocytosis and increased hepatic enzymes were reported most often.[Ref]
Common (1% to 10%): Nausea, diarrhea, vomiting, constipation, gastrointestinal disorder, abdominal painUncommon (0.1% to 1%): Oral moniliasis/candidiasis, flatulence, ileus, dyspepsia, intestinal obstructionFrequency not reported: Clostridium difficile associated diarrhea, antibiotic-associated colitis, pseudomembranous colitis[Ref]
Common (1% to 10%): HeadacheUncommon (0.1% to 1%): Dizziness, seizure, paresthesia, somnolence, syncope, astheniaFrequency not reported: Hearing loss, other adverse central nervous system (CNS) experiences[Ref]
Seizures and other adverse CNS experiences have been reported.  They have occurred most commonly in patients with CNS disorders (e.g., history of seizures, brain lesions) or with bacterial meningitis and/or renal dysfunction.Seizures occurred more often in patients with moderately severe renal dysfunction.[Ref]
Common (1% to 10%): Anemia, hypochromic anemia, bleeding events (including gastrointestinal hemorrhage, melena, epistaxis, hemoperitoneum), thrombocythemiaUncommon (0.1% to 1%): Increased platelets, increased eosinophils, decreased platelets, decreased hemoglobin, decreased hematocrit, decreased white blood cells, decreased prothrombin time, decreased partial thromboplastin time, leukocytosis, eosinophilia, thrombocytopenia, leukopenia, neutropeniaPostmarketing reports: Agranulocytosis, positive Coombs test (direct or indirect), hemolytic anemia[Ref]
Shock occurred more often in patients with moderately severe renal dysfunction.[Ref]
Common (1% to 10%): Pain, inflammation, sepsis/septicemia, shock, accidental injuryUncommon (0.1% to 1%): Chest pain, fever, back pain, chills, pelvic pain, peripheral edema, abdominal enlargement[Ref]
Common (1% to 10%): Inflammation at the injection site, phlebitis/thrombophlebitis, pain at the injection siteUncommon (0.1% to 1%): Injection site reactions, edema at the injection site[Ref]
Common (1% to 10%): Rash (including diaper/nappy area moniliasis), pruritusUncommon (0.1% to 1%): Urticaria, sweating, skin ulcerPostmarketing reports: Toxic epidermal necrolysis, Stevens-Johnson syndrome, angioedema, erythema multiforme, severe skin reactions[Ref]
Common (1% to 10%): Apnea, pharyngitis, pneumoniaUncommon (0.1% to 1%): Respiratory disorder, dyspnea, pleural effusion, asthma, increased cough, hypoxia, lung edemaFrequency not reported: Respiratory failure[Ref]
Heart failure occurred more often in patients with moderately severe renal dysfunction.[Ref]
Common (1% to 10%): Peripheral vascular disorderUncommon (0.1% to 1%): Heart failure, heart arrest, tachycardia, hypertension, myocardial infarction, pulmonary embolus, bradycardia, hypotension[Ref]
Common (1% to 10%): Increased transaminasesUncommon (0.1% to 1%): Increased AST, increased ALT, increased bilirubin, hepatic failure, cholestatic jaundice/jaundice[Ref]
Common (1% to 10%): Hypoglycemia, increased alkaline phosphatase, increased lactate dehydrogenaseUncommon (0.1% to 1%): Anorexia, hypervolemia, hypokalemia[Ref]
Kidney failure occurred more often in patients with moderately severe renal dysfunction.[Ref]
Uncommon (0.1% to 1%): Kidney failure, increased creatinine, increased BUN[Ref]
Uncommon (0.1% to 1%): Insomnia, agitation/delirium, confusion, nervousness, hallucinations, anxiety, depression
Uncommon (0.1% to 1%): Dysuria, vaginal moniliasis/candidiasis, urinary incontinence, red blood cells in urine[Ref]
Frequency not reported: Serum sickness-like reactions, cross-sensitivity in penicillin-allergic and cephalosporin-allergic patients, anaphylaxis[Ref]
Frequency not reported: Myalgia, arthralgia[Ref]
1. "Product Information. Merrem (meropenem)." Zeneca Pharmaceuticals, Wilmington, DE. 
2. Cerner Multum,  Inc. "Australian Product Information." O 0
3. Zhanel GG,  Wiebe R,  Dilay L, et al. "Comparative Review of the Carbapenems." Drugs 67 (2007): 1027-1052
4. Baldwin CM,  Lyseng-Williamson KA,  Keam SJ "Meropenem : a review of its use in the treatment of serious bacterial infections." Drugs 68 (2008): 803-38
5. Wilson SE "Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections." Clin Infect Dis 24 Suppl 2 (1997): s197-206
6. Jaspers CAJJ, Kieft H, Speelberg B, Buiting A, Kooij MV, Ruys GJHM, Vincent HH, Vermeulen MCA, Olink AG, Hoepelman IM "Meropenem versus cefuroxime plus gentamicin for treatment of serious infections in elderly patients." Antimicrob Agents Chemother 42 (1998): 1233-8
7. Embil JM,  Soto NE,  Melnick DA "A post hoc subgroup analysis of meropenem versus imipenem/cilastatin in a multicenter, double-blind, randomized study of complicated skin and skin-structure infections in patients with diabetes mellitus." Clin Ther 28 (2006): 1164-74
8. Hemsell DL, Martens MG, Faro S, Gall S, Mcgregor JA "A multicenter study comparing intravenous meropenem with clindamycin plus gentamicin for the treatment of acute gynecologic and obstetric pelvic infections in hospitalized women." Clin Infect Dis 24 ( Suppl (1997): s222-30
9. Kempf P, Bauernfeind A, Muller A, Blum J "Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections." Infection 24 (1996): 473-9
10. Shah PM, Heller A, Fuhr HG, Walther F, Halir S, Schaumann R, Bohme A, Jung B, Kohler A, Lipsschulte C, Stille W "Empirical monotherapy with meropenem versus imipenem/cilastatin for febrile episodes in neutropenic patients." Infection 24 (1996): 480-4
11. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ "The pharmacokinetics of meropenem in volunteers." J Antimicrob Chemother 24(suppl a (1989): 311-20
12. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
13. Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR "Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males." Eur J Clin Microbiol Infect Dis 10 (1991): 85-8
14. Mouton YJ, Beuscart C "Empirical monotherapy with meropenem in serious bacterial infections. Meropenem Study Group." J Antimicrob Chemother 36(suppl a (1995): 145-56
15. Huizinga WK, Warren BL, Baker LW, Valleur P, Pezet DM, Hoogkamp-Korstanjep JA, Karran SJ "Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections." J Antimicrob Chemother 36(suppl a (1995): 179-89
16. Byrne S, Maddison J, Connor P, Doughty I, Dodd M, Jenney M, Webb AK, David TJ "Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients." J Antimicrob Chemother 36(suppl a (1995): 135-43
17. Hamacher J, Vogel F, Lichey J, Kohl FV, Diwok K, Wendel H, Lode H "Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease in hospitalised patients--a comparison of meropenem and imipenem/cilastatin. COPD Study Group." J Antimicrob Chemother 36(suppl a (1995): 121-33
18. Liu TJ,  Lam JP "Piperacillin-tazobactam-induced acute interstitial nephritis with possible meropenem cross-sensitivity in a patient with osteomyelitis." Am J Health Syst Pharm 69 (2012): 1109
19. Paquet P,  Jacob E,  Damas P,  Pierard GE "Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell's syndrome) after putative beta-lactam cross-reactivity: Case report and scrutiny of antibiotic imputability." Crit Care Med 30 (2002): 2580-3
20. Ralph ED,  John M,  Rieder MJ,  Bombassaro AM "Serum Sickness-like Reaction Possibly Associated with Meropenem Use." Clin Infect Dis 36 (2003): E149-E151
Not all side effects for Merrem may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

Redness and swelling at the injection site


Bluish lips or skin
chills
cold, clammy skin
confusion
dizziness
fainting
fast heartbeat
fast, weak pulse
fever
itching skin
lightheadedness
not breathing
pain at the injection site
rapid, shallow breathing
skin rash and itching
sweating


Abdominal or stomach cramps and severe pain
agitation
black, bloody, or tarry stools
black, bloody vomit
bloating or swelling of the face, arms, hands, lower legs, or feet
blurred vision
burning while urinating
burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
convulsions (seizures)
cough
dark urine
decreased urine output
depression
diarrhea (watery and severe), which may also be bloody
difficult or painful urination
difficulty with breathing
dilated neck veins
extreme fatigue
fever with or without chills
headache
hostility
irregular breathing
irritability
lethargy
light-colored stools
loss of consciousness
muscle twitching
nausea
no blood pressure or pulse
nosebleed
pale skin
pounding in the ears
rapid weight gain
severe constipation
severe vomiting
slow, irregular heartbeat
stopping of the heart
stupor
tightness in the chest
troubled breathing with exertion
unconsciousness
unpleasant breath odor
unusual bleeding or bruising
unusual tiredness or weakness
unusual weight gain or loss
vomiting of blood or material that looks like coffee grounds
weight gain
yellow eyes or skin


Back, leg, or stomach pains
bleeding gums
blistering, peeling, or loosening of the skin
chest pain
cough or hoarseness
general body swelling
general feeling of tiredness or weakness
joint or muscle pain
large, hive-like swelling on the face, eyelids, tongue, throat, hands, legs, feet, or sex organs
loss of appetite
lower back or side pain
red skin lesions, often with a purple center
red, irritated eyes
sore throat
sores, ulcers, or white spots in the mouth or on the lips
swollen glands


Constipation


Body aches or pain
cold hands and feet
cold sweats
congestion
cool pale skin
dryness or soreness of the throat
increased hunger
indigestion
nightmares
passing of gas
redness, swelling, or soreness of the tongue
runny nose
shakiness
slurred speech
sneezing
stomach pain, fullness, or discomfort
trouble swallowing
vaginal yeast infection
voice changes


Acid or sour stomach
belching
excess air or gas in the stomach or intestines
full feeling
heartburn
hives or welts
redness of the skin
seeing, hearing, or feeling things that are not there
sleepiness or unusual drowsiness
trouble sleeping
white patches in the mouth, tongue, or throat

